Compare INDP & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | CGC |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.4M | 401.0M |
| IPO Year | 2021 | 2023 |
| Metric | INDP | CGC |
|---|---|---|
| Price | $2.63 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.1K | ★ 3.5M |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $0.84 |
| 52 Week High | $10.57 | $2.38 |
| Indicator | INDP | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 33.83 |
| Support Level | $2.42 | $0.84 |
| Resistance Level | $3.08 | $1.23 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 54.55 | 16.45 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.